Literature DB >> 17239983

Comparison of pathologic findings of baseline and annual repeat cancers diagnosed on CT screening.

Darryl Carter1, Madeline Vazquez, Douglas B Flieder, Elizabeth Brambilla, Adi Gazdar, Masayuki Noguchi, William D Travis, Arin Kramer, Rowena Yip, David F Yankelevitz, Claudia I Henschke.   

Abstract

Screening for lung cancer produces two groups of lung cancers. Baseline cases include all prevalent cases with the expectation that slower-growing cancers and those that have achieved higher stage will be found in greater frequency. Repeat examination is expected to detect those cancers which have crossed the threshold for detection during the screening interval - 1 year in this study - and these are typically more rapidly growing cancers. The two groups encompass the full spectrum of lung cancers. Comparison of the baseline and annual repeat cases revealed differences in types of lung cancer. There were 202 baseline-detected cancers spanning the spectrum of pulmonary neoplasms with some slowly growing, some rapidly progressive and some at high stage; the 48 annual repeat cancers also included a spectrum of lung cancers but with more of the rapidly growing types, and more closely approximated the clinical spectrum of lung cancers. The NE carcinomas showed this trend best; small-cell carcinomas were under-represented and typical carcinoids were only found in the baseline group. Repeat cancers were found to grow rapidly, were typically smaller, less often multiple and the adenocarcinomas were less often pure BAC and less frequently contained a BAC component when invasive. The baseline adenocarcinomas included most of the BAC's, which is a diagnosis that requires special attention to its WHO definition. AAH was found to be frequently associated with adenocarcinoma, particularly BAC. Both baseline and annual repeat cases had a high percentage of invasive carcinomas with comparably high rates of resectability, high rates of node negativity and consequently a high proportion of cases in low stage.

Entities:  

Mesh:

Year:  2007        PMID: 17239983     DOI: 10.1016/j.lungcan.2006.12.001

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  23 in total

Review 1.  Small pulmonary nodules in baseline and incidence screening rounds of low-dose CT lung cancer screening.

Authors:  Joan E Walter; Marjolein A Heuvelmans; Matthijs Oudkerk
Journal:  Transl Lung Cancer Res       Date:  2017-02

Review 2.  Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management.

Authors:  Talal Hilal
Journal:  Ther Adv Med Oncol       Date:  2016-11-17       Impact factor: 8.168

3.  Aberrant methylation of mutL homolog 1 is associated with increased risk of non-small cell lung cancer.

Authors:  Haochang Hu; Xiaoying Chen; Cong Zhou; Bin Li; Yong Yang; Xiuru Ying; Yiyi Mao; Yihan Zhang; Jie Zhong; Jie Dai; Hang Yu; Boyi Wu; Xiaodong Li; Tiangong Wang; Shiwei Duan
Journal:  J Clin Lab Anal       Date:  2017-12-05       Impact factor: 2.352

4.  CT Screening for Lung Cancer: Nonsolid Nodules in Baseline and Annual Repeat Rounds.

Authors:  David F Yankelevitz; Rowena Yip; James P Smith; Mingzhu Liang; Ying Liu; Dong Ming Xu; Mary M Salvatore; Andrea S Wolf; Raja M Flores; Claudia I Henschke
Journal:  Radiology       Date:  2015-06-23       Impact factor: 11.105

5.  Offering lung cancer screening to high-risk medicare beneficiaries saves lives and is cost-effective: an actuarial analysis.

Authors:  Bruce S Pyenson; Claudia I Henschke; David F Yankelevitz; Rowena Yip; Ellynne Dec
Journal:  Am Health Drug Benefits       Date:  2014-08

6.  Computed Tomography Screening for Lung Cancer: Mediastinal Lymph Node Resection in Stage IA Nonsmall Cell Lung Cancer Manifesting as Subsolid and Solid Nodules.

Authors:  Raja M Flores; Daniel Nicastri; Thomas Bauer; Ralph Aye; Shahriyour Andaz; Leslie Kohman; Barry Sheppard; William Mayfield; Richard Thurer; Robert Korst; Michaela Straznicka; Fred Grannis; Harvey Pass; Cliff Connery; Rowena Yip; James P Smith; David F Yankelevitz; Claudia I Henschke; Nasser K Altorki
Journal:  Ann Surg       Date:  2017-05       Impact factor: 12.969

7.  Lung cancers diagnosed at annual CT screening: volume doubling times.

Authors:  Claudia I Henschke; David F Yankelevitz; Rowena Yip; Anthony P Reeves; Ali Farooqi; Dongming Xu; James P Smith; Daniel M Libby; Mark W Pasmantier; Olli S Miettinen
Journal:  Radiology       Date:  2012-03-27       Impact factor: 11.105

8.  Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications.

Authors:  Madeline Vazquez; Darryl Carter; Elizabeth Brambilla; Adi Gazdar; Masayuki Noguchi; William D Travis; Yao Huang; Lijuan Zhang; Rowena Yip; David F Yankelevitz; Claudia I Henschke
Journal:  Lung Cancer       Date:  2008-10-31       Impact factor: 5.705

Review 9.  The importance of the regimen of screening in maximizing the benefit and minimizing the harms.

Authors:  Claudia I Henschke; Kunwei Li; Rowena Yip; Mary Salvatore; David F Yankelevitz
Journal:  Ann Transl Med       Date:  2016-04

10.  What is a reasonable cost to refute a preposterous hypothesis?

Authors:  A W Castleberry; F W Grannis
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.